Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: A double-blind, randomized, placebo-controlled, parallel-group study

Journal of Clinical Psychiatry

Volumn 69, Issue 4, 2008, Pages 571-577

  Bielski, Robert J ^a   Cunningham, Lynn ^b   Horrigan, Joseph P ^c   Londborg, Peter D ^d   Smith, Ward T ^e   Weiss, Kenneth ^f  

^a Summit Research Network   (United States)

^b Cunningham Clinical Research   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Summit Research Network   (United States)

^e Summit Research Network   (United States)

^f Delaware Valley Research Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEPIRONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 44849128731     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0408     Document Type: Article

References (24)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
2. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization; 2001. Available at: http://www.who.int/whr/2001/en/whr01_en.pdf. Accessed April 17, 2007
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917
4. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007;88(suppl 2):S61-S71
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
6. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-1264
7. Cryan JF, Leonard BE. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 2000;15:113-135
8. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 1998;59(suppl 18):23-29
9. Amsterdam JD. Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:271-280
10. Bosker FJ, Westerink BH, Cremers TI, et al. Future antidepressants: what is in the pipeline and what is missing? CNS Drugs 2004;18:705-732
11. Jenkins SW, Robinson DS, Fabre LF Jr, et al. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990;10(suppl 3):77S-85S
12. McGrath PJ, Stewart JW, Quitkin FM, et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 1994;14:347-352
13. Robinson DS, Sitsen JM, Gibertini M. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clin Ther 2003;25:1618-1633
14. Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987;1:470-480
15. Blier P, de Montigny C. Electrophysiological investigation of the adaptive response of the 5-HT system to the administration of 5-HT1A receptor agonists. J Cardiovasc Pharmacol 1990;15(suppl 7):S42-S48
16. Gartside SE, Umbers V, Hajos M, et al. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995;115:1064-1070
17. Timmer CJ, Sitsen JM. Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. J Pharm Sci 2003;92:1773-1778
18. Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003;64:243-249
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Dept Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976
22. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-747
23. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002;106:252-264
24. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-557